Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS)


Benign prostatic hyperplasia (BPH) is defined histologically. Several terms such as "prostatism", "symptoms of BPH", and "clinical BPH" have previously been used to describe male lower urinary tract symptoms (LUTS). These descriptions incorrectly imply that urinary symptoms in the male arise from the prostate. The acronym "LUTS" was introduced in order to avoid this. Increasingly, scientific communications on this syndrome use the term LUTS and avoid the use of the global term BPH. Nevertheless, BPH remains familiar to and commonly used by general practitioners, other clinicians, and patients when searching for clinical information and guidance. Clinically, the syndrome is characterised by lower urinary tract symptoms (urinary frequency, urgency, a weak and intermittent stream, needing to strain, a sense of incomplete emptying, and nocturia) and can lead to complications, including acute urinary retention.

Latest guidelines

Latest citations

Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials. ( 25 September 2015 )

Tibial Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review. ( 25 September 2015 )